RLAY (Relay Therapeutics) Common Stock : $0.17 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Relay Therapeutics Common Stock?

Relay Therapeutics's quarterly common stock increased from Mar. 2024 ($0.13 Mil) to Jun. 2024 ($0.13 Mil) and increased from Jun. 2024 ($0.13 Mil) to Sep. 2024 ($0.17 Mil).

Relay Therapeutics's annual common stock increased from Dec. 2021 ($0.11 Mil) to Dec. 2022 ($0.12 Mil) and increased from Dec. 2022 ($0.12 Mil) to Dec. 2023 ($0.13 Mil).

Relay Therapeutics Common Stock Historical Data

The historical data trend for Relay Therapeutics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relay Therapeutics Common Stock Chart

Relay Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.09

0.11

0.12

0.13

Relay Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Common Stock	Get a 7-Day Free Trial															0.12	0.13	0.13	0.13	0.17

Relay Therapeutics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Relay Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relay Therapeutics Inc (NAS:RLAY) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

N/A

Address

399 Binney Street, 2nd Floor, Cambridge, MA, USA, 02139

Website

https://www.relaytx.com

Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).

Executives

Thomas Catinazzo	officer: Vice President, Finance	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Peter Rahmer	officer: See remarks	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139
Donald A Bergstrom	officer: See Remarks	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Brian Adams	officer: General Counsel	750 LEXINGTON AVENUE, NEW YORK NY 10022
Sanjiv Patel	director, officer: President and CEO	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Andy Porter	officer: See Remarks	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Mark Murcko	director	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Sekar Kathiresan	director	500 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Third Rock Ventures Iii, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Jami Rubin	director	C/O RELAY THERAPEUTICS, INC., 399 BINNEY STREET, CAMBRIDGE MA 02139
Douglas S Ingram	director	2525 DUPONT DR, IRVINE CA 92612
Third Rock Ventures Gp Iv, L.p.	10 percent owner	29 NEWBURY STREET, 3RD FLOOR, BOSTON MA 02116
Svf Pauling (cayman) Ltd	10 percent owner	27 HOSPITAL ROAD, GEORGE TOWN, GEORGE TOWN E9 KY1-9008
Picularium, Llc	10 percent owner	1166 AVENUE OF THE AMERICAS, NINTH FLOOR, NEW YORK NY 10036
Laura Shawver	director	1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518